Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, Pfizer and hemophilia
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi,
FDA approves first once-weekly drug treatment regimen for hemophilia
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first once-weekly treatment for the disease.
Pfizer’s Hympavzi Approved for Treatment of Certain Types of Hemophilia
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a week.
Pfizer’s Hympavzi Wins FDA Approval to Treat Hemophilia
Pfizer Inc.’s Hympavzi won US approval to treat hemophilia, a potentially deadly genetic disorder that prevents blood from clotting properly.
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient.
Pfizer gets FDA approval for Hympavzi for hemophilia
Pfizer (NYSE:PFE) said the FDA has approved its drug Hympavzi for the treatment of certain types of hemophilia. The agency approved Hympavzi as a routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients aged 12 years and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX
Pfizer, Starboard
An Activist Investor Just Bought $1 Billion Worth of Pfizer. Here's What It Means for the Stock
On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -2.82%) that's worth approximately $1 billion. Now, Starboard will aim to work with the company's management as well as consult with former executives -- all with the aim of turning around Pfizer's sagging fortunes.
Pfizer’s stock dips after two former execs say they won’t support Starboard
Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were “threatened” into backing current management.
Activist investor Starboard cries foul play in exec U-turn at Pfizer
Starboard has accused Pfizer of “coercive conduct” after executives who initially backed the hedge fund retracted their support.
FiercePharma
1d
Activist investor Starboard accuses Pfizer of strong-arming former execs into backing CEO Bourla ahead of strategy meeting
Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...
19h
on MSN
Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis
Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...
MM&M
4d
Activist investor takes $1B stake in Pfizer, aims to turn around company
Citing people familiar with the matter, The Journal reported that Starboard approached former Pfizer CEO Ian Read and CFO ...
3d
Pfizer: A Strong Product Pipeline Could Lead To Significant Upside
Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...
7h
Royalty Pharma Declares Fourth Quarter 2024 Dividend
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ...
1d
on MSN
Pfizer fight with Starboard heats up, hedge fund alleges executive pressure
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback